Business Context and Reporting Period
Company: AmerisourceBergen Corporation (Note: The filing is for AmerisourceBergen, formed by the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. The user prompt mentions "Cencora," which is the company's current name following a 2023 rebranding; this 2001 filing predates that name change).
Reporting Period: Fiscal Year Ended September 30, 2001.
Key Event: The Company was formed on August 29, 2001, via the merger of AmeriSource and Bergen. The financial results for fiscal 2001 include a full year of AmeriSource operations and approximately one month of Bergen operations. The merger was accounted for under the purchase method, resulting in the recording of approximately $2.3 billion in goodwill and intangible assets.
Operations: The Company operates as the largest pharmaceutical services company in the U.S., organized into two segments: Pharmaceutical Distribution (wholesale and specialty drug distribution) and PharMerica (institutional pharmacy services).
Key Financial Metrics
| Metric | Fiscal 2001 | Fiscal 2000 |
|---|---|---|
| Operating Revenue | $15.82 billion | $11.61 billion |
| Total Revenue (incl. bulk deliveries) | $16.19 billion | $11.65 billion |
| Gross Profit | $700.1 million | $519.6 million |
| Gross Margin | 4.42% | 4.48% |
| Operating Income | $259.4 million | $202.1 million |
| Net Income | $123.8 million | $99.0 million |
| Diluted EPS | $2.10 | $1.90 |
| Total Assets | $10.29 billion | $2.46 billion |
| Long-Term Debt (incl. current) | $1.60 billion | $413.7 million |
| Cash and Equivalents | $297.6 million | $120.8 million |
| Operating Cash Flow | ($40.0 million) used | $216.6 million provided |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 36% to $15.8 billion. Excluding the merger impact, organic revenue growth was 20%. Pro forma combined revenue increased 14% year-over-year.
- Profitability: Net income increased 25% to $123.8 million. Adjusted net income (excluding special items) increased 39%.
- Balance Sheet Expansion: Total assets grew from $2.46 billion to $10.29 billion, primarily due to the acquisition of Bergen's assets and the recording of $2.13 billion in goodwill.
- Debt Structure: Long-term debt increased significantly to $1.60 billion to finance the merger. The Company issued $500 million in 8 1/8% senior notes and entered a $1.3 billion senior secured credit facility.
- Cash Flow: Operating cash flow turned negative ($40.0 million used) compared to a positive $216.6 million in 2000. This was driven by a $726 million increase in merchandise inventories and a $152 million increase in accounts receivable, partially offset by a $619 million increase in accounts payable.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Integration Synergies: Management expects to achieve approximately $150 million in annual synergies by the end of the third year post-merger through facility consolidation and elimination of duplicate functions.
- Facility Consolidation: Plans to reduce distribution facilities from 51 to approximately 30 over the next 3-4 years. A charge of $10.9 million was recognized in Q4 2001 for initial closures.
- Dividends: The Company initiated a quarterly cash dividend of $0.025 per share, paid on December 3, 2001.
- Capital Expenditures: Expected to be between $85 million and $95 million for fiscal 2002.
Risks and Contingencies
- Regulatory Environment: The Company faces risks related to Medicare Prospective Payment System (PPS) changes and Medicaid reimbursement reductions, particularly affecting the PharMerica segment.
- Legal Proceedings:
- Antitrust: Ongoing class action lawsuits alleging price-fixing (though federal claims were dismissed, appeals and state cases remain).
- Proposition 65: Litigation regarding coal tar in dandruff shampoos; trial scheduled for January 2002.
- PharMerica Matters: Securities class actions and potential liability related to false Medicare claims by a former nursing home chain (Sensitive Care).
- Environmental: A remaining liability of $1.0 million for remediation at a former distribution center, though $2.7 million in reserves were reversed into income in 2001.
- Customer Concentration: The Veterans Administration represented 16% of operating revenue in fiscal 2001.
Investor Verification Checklist
- Merger Integration Progress: Verify the timeline and cost realization of the planned facility consolidations and the $150 million synergy target.
- Working Capital Management: Monitor the trend in inventory levels and accounts receivable, which drove negative operating cash flow in 2001.
- Debt Servicing: Assess the impact of the increased debt load ($1.6 billion) on future interest expenses and liquidity, particularly with the new 8 1/8% notes.
- Regulatory Impact: Track changes in Medicaid and Medicare reimbursement rates, specifically regarding the PharMerica segment's margins.
- Legal Exposure: Review the status of the antitrust appeals and the Proposition 65 trial scheduled for early 2002.